tbuckley/cabot-search huggingface dataset:
Oracle Bones
Authors: Richard Donze
Journal: Annals of Internal Medicine (2009)

Ad Libitum20 October 2009Oracle BonesRichard Donze, DO, MPHRichard Donze, DO, MPHFrom West Chester, PA 19380-6706.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-8-200910200-00010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail He'd already seen thenew slides and knew an“oh no” would come withthe old; tried to imagine hiscross-county counterpartpushing the glass—maybeit was so late the charms ofso many polka-dot nucleilulled the usually clear headand sharp eyes into benigncomfort and simply notseeing what he was seeingnow on the kind of Monday-morning re-read he hated—the few cracked black eggsat the slide's edge spillingspindly sprigs of blackermitotic yolk onto violetswirl like the unread scripton oracle bones; andnothing; go ... Author, Article, and Disclosure InformationAffiliations: From West Chester, PA 19380-6706.Current Author Address: Richard Donze, DO, MPH, 241 Cheshire Circle, West Chester, PA 19380-6706. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 October 2009Volume 151, Issue 8Page: 565KeywordsBoneFemur ePublished: 20 October 2009 Issue Published: 20 October 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
RELATION OF GYNECOLOGY TO NEUROLOGY
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnostic medical radiation in inflammatory bowel disease: primum non-nocere?
Authors: R. O. Butcher, E. Nixon, C. Robertson, M. Sapundzieski, R. Filobbos, J. K. Limdi
Journal: Gut (2011)

<h3>Introduction</h3> Patients with inflammatory bowel disease (IBD) are frequently exposed to diagnostic medical radiation for the diagnosis and evaluation of their disease. Despite increasing awareness of the potentially serious downstream effects, few studies have quantified radiation exposure in IBD patients. <h3>Methods</h3> We conducted a retrospective review of 220 consecutive patients attending IBD clinics at our hospital. Clinical data including demographics, disease characteristics and therapy were obtained from case note and electronic patient record review. All incidences of diagnostic medical radiation from initial diagnosis until 30 June 2010 inclusive were recorded from case note and computerised radiology database system review. The radiation dose for each procedure was obtained from published tables from the Royal College of Radiologists, UK. Effective dose for each procedure was calculated by multiplying this value by the number of procedures during the study period. The sum of doses received was the cumulative effective dose. <h3>Results</h3> One hundred and one of the 220 IBD patients reviewed were female, 119 were male. The median age was 48 (range 17–88) and mean disease duration 10 years. One hundred and one patients had Crohn9s disease, 111 patients had ulcerative colitis and 8 patients had an indeterminate colitis. The mean and median cumulative effective radiation doses were 11.61 mSv and 7.21 mSv respectively. A cumulative radiation dose greater than 10 mSv was seen in 41.8% (92) patients and greater than 25 mSv in 13.2% (29) patients. In 9 patients the cumulative effective dose was greater than 50 mSv. Crohn9s disease was associated with a higher cumulative effective dose with exposure exceeding 10 mSv in 62.4%, 25 mSv in 22.8% and 50 mSv in 8.9% patients respectively. CT imaging accounted for 43% and barium studies for 32% of the total cumulative effective dose exposure. Thirty-nine of these patients had small bowel magnetic resonance (MR) studies in the last 2 years as an alternative to ionising radiation procedures. <h3>Conclusion</h3> Patients with IBD, particularly those with Crohn9s disease are exposed to significant amounts of diagnostic medical radiation in their lifetime. The increased risk of cancer from cumulative radiation coupled with the inherent risk of colorectal malignancy in long standing IBD and the potential for immunomodulator drugs such as azathioprine to increase the risk of cancers (eg lymphoma) is of great clinical and public health concern. Clinicians must remain vigilant to these risks when evaluating these patients and radiation exposure should be minimised and where possible alternatives such as intestinal ultrasound and MR imaging preferred.
Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients
Authors: E. Verzoni, A. Cova, P. Squarcina, L. De Cecco, D. Rinchai, D. Bedognetti, P. Grassi, R. Ratta, G. Procopio, L. Rivoltini
Journal: Annals of Oncology (2017)
William Osler and Bartholomaeus Anglicus' De proprietatibus rerum
Authors: R. P. Howard
Journal: JAMA (1969)

William Osler (1849-1919) was the beloved physician of his age. He inspired his associates, students, patients, and friends wherever he encountered them. The bonds were lasting through his lifetime and those of his acquaintances too. His influence on members of the medical profession and many allied fields was indeed a "potent ferment" and burned deeply into the hearts of those who knew him<sup>1</sup>(the author's grandfather used the phrase "potent ferment" in a letter to Osler in 1884). Through their spoken tributes and his own deeds and writings, Osler's name is engraved with honor on the minds of untold numbers in the succeeding generations of men and women. Osler's fame today may be ascribed to many things, among which are his writings and his love of books.<i>The Principles and Practice of Medicine</i>in 1892 established his preeminence as a talented medical writer.<sup>2</sup>It rapidly became the standard
A 3-year randomized controlled study with sublingual immunotherapy in mite-induced respiratory allergy
Authors: C. Lombardi, G. Passalacqua, R. Ariano, M. Pasquali, I. Baiardini, A. Giardini, G. Majani, M. Bruno, P. Falagiani, G.W. Canonica
Journal: Journal of Allergy and Clinical Immunology (2005)
Management of Pyelonephritis
Authors: Harry A. Derow
Journal: New England Journal of Medicine (1956)

DiagnosisLongcope and Winkenwerder36 emphasized the diagnostic challenge that pyelonephritis presents as follows:From the significant data that are now available, it should be possible to recognize this form of renal disease long before the critical stage has been reached in the destruction of renal tissue.Of fundamental importance in the diagnosis of pyelonephritis is the need for the physician to appreciate that the symptomatology, if present, may or may not suggest urinary-tract involvement and that careful urinalysis and bacteriologic study of the urine often reveal abnormalities that may be consistent with the disease.It must be emphasized that the . . .
ITALY
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE YIELD AND PROGNOSTIC VALUE OF SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MYOCARDIAL PERFUSION IMAGING (MPI) IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) IN THE PRE-OPERATIVE SETTING: ABNORMAL TESTS DO NOT PREDICT MEDIUM-TERM MORTALITY
Authors: Rony Lahoud, Wael Jaber, Maan Fares, Ellen Mayer Sabik, Richard Brunken, Venu Menon
Journal: Journal of the American College of Cardiology (2016)
Adolescents and their music: Paganini, Satanists, and insider trading
Authors: J. Di Saia
Journal: JAMA (1990)

<h3>To the Editor.—</h3> The article by Drs Brown and Hendee<sup>1</sup>on music in adolescence addresses several salient points about the importance of music to the adolescent; however, in targeting heavy metal it becomes very much typical of the media's assault on this form of music. Drs Brown and Hendee direct their discussion toward a form of music that they never really define clearly. Is all music with a "loud beat and performers with aggressive and startling stage antics" heavy metal? In his age, Niccolò Paganini was known similarly. Then, is the work of Paganini heavy metal? As is typical of these discussions, the different categories within the genre are not identified (ie, power pop, hardcore/ thrash, progressive, and neoclassicalfusion). Is all heavy metal correlated with poor school performance? Drs Brown and Hendee cite Roe,<sup>2</sup>stating that "music preferences are dependent on earlier levels of school achievement." It seems
Health benefits of tennis
Authors: Babette M Pluim, J Bart Staal, Bonita L Marks, Stuart Miller, Dave Miley
Journal: British Journal of Sports Medicine (2007)

The aim of the study was to explore the role of tennis in the promotion of health and prevention of disease. The focus was on risk factors and diseases related to a sedentary lifestyle, including low fitness levels, obesity, hyperlipidaemia, hypertension, diabetes mellitus, cardiovascular disease, and osteoporosis. A literature search was undertaken to retrieve relevant articles. Structured computer searches of PubMed, Embase, and CINAHL were undertaken, along with hand searching of key journals and reference lists to locate relevant studies published up to March 2007. These had to be cohort studies (of either cross sectional or longitudinal design), case–control studies, or experimental studies. Twenty four studies were identified that dealt with physical fitness of tennis players, including 17 on intensity of play and 16 on maximum oxygen uptake; 17 investigated the relation between tennis and (risk factors for) cardiovascular disease; and 22 examined the effect of tennis on bone health. People who choose to play tennis appear to have significant health benefits, including improved aerobic fitness, a lower body fat percentage, a more favourable lipid profile, reduced risk for developing cardiovascular disease, and improved bone health.
Course Abstracts
Authors: John Barber, Badrudin Kurwa, L Lohr, Herve Byron, Malcolm Mccannel, Craig George, James Atwood, Richard Chenoweth, Owen Sipperley, San Antonio, Howard Cupples, Michael Easterbrook, Paul Yinger, Gerald Fonda, David Karan, Joel Kraut, Jack Hartstein, St Louis, Joseph Baldone, Thomas Hedges, John Mccrary Ill, Thomas Hedges Ill, Richard Mills, John Hetherington, H Dunbar Hoskins, Robert Shaffer, San Francisco, Paul Lichter, Ann Arbor, Kenneth Richardson, Richard Simmons, George Spaeth, Kenneth Hoffer, Santa Monica, Miles Galin, New York, Manus Kraff, David Mcintyre, Creig Hoyt, John Flynn, Los Angeles, James Katowitz, Richard Carroll, Richard Dortzbach, Steven Kramer, John Stanley, Jorge Alvarado, John Lynn, Ralph Crump, Richard Schultz, Steven Koenig, Robert Hyndiuk, Jay Krachmer, Iowa City, Robert Poirier, Stephen Sinclair, Juan Grunwald, David 5011, Pa Orkan, George Stasi Or, Robert Waller, John Wobig, Nathanael Bradley, W Lemke, Joseph Flanagan
Journal: Ophthalmology (1983)
Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake
Authors: Kevin D. Hall, Alexis Ayuketah, Robert Brychta, Hongyi Cai, Thomas Cassimatis, Kong Y. Chen, Stephanie T. Chung, Elise Costa, Amber Courville, Valerie Darcey, Laura A. Fletcher, Ciaran G. Forde, Ahmed M. Gharib, Juen Guo, Rebecca Howard, Paule V. Joseph, Suzanne McGehee, Ronald Ouwerkerk, Klaudia Raisinger, Irene Rozga, Michael Stagliano, Mary Walter, Peter J. Walter, Shanna Yang, Megan Zhou
Journal: Cell Metabolism (2020)
Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docetaxel (T) and platinums (C, cisplatin or carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC)
Authors: D. Slamon, C. H. Yeon, T. Pienkowski, D. Northfelt, W. Eiermann, R. Patel, J. Crown, A. Riva, S. Blitz, M. Pegram
Journal: Journal of Clinical Oncology (2004)

642 Background: In preclinical models, T and C are synergistic in combination with H. Support for these observations has been observed in two recently reported randomized clinical trials: (1) addition of C to paclitaxel (P)+H significantly increased overall response rate (ORR) and time to progression, and (2) addition of H to T resulted in improved overall survival (OS) for HER2+ ABC. Synergy, along with need to develop non-anthracycline regimens for combination with H, led to two phase II studies to evaluate the safety and efficacy of T+H in combination with either cisplatin or carboplatin. Methods: ABC patients with HER2+ tumors by immunohistochemistry (IHC, 2+/3+) or fluorescence in situ hybridization (FISH) were treated with T+cisplatin+H (TCisH, n=62) or T+carboplatin+H (TCarboH, n=62). Retrospective FISH analysis was performed on all available tumors. T (75 mg/m2) and cisplatin (75 mg/m2) or carboplatin (AUC 6) were given on day 2 and then q21d for a median of 6 cycles. H was given on day 1 (4 mg/kg) and then weekly (2 mg/kg) thereafter. Results: ORR among all evaluable patients was 79% (95% Confidence Interval [CI], 66–89%) for TCisH (n=62) and 58% (CI, 44–70%) for TCarboH (n=59). For FISH(+) patients, ORRs were 77% (CI, 59–90%) for TCisH and 62.5% (CI, 46–77%) for TCarboH. With median follow-up (F/U) of 37.7 months for TCisH, median OS for all patients was 28.1 months (CI, 18.2-Not Estimable [NE]). Median OS was 27.0 months (CI, 18.1-NE) in the FISH(+) subgroup and 31.5 months (CI, 14.0-NE) for the FISH(-) subgroup. With median F/U of 34.3 months for TCarboH, median OS has not yet been reached with 34/62 patients (54.8%) remaining alive. Conclusions: TCH combinations are active in HER2+ ABC patients. The median OS of 28.1 months for TCisH and >34.3 months for TCarboH are the longest yet reported for a HER2+ ABC population, and compare favorably with the 22.1 month OS reported previously for P+H. Randomized phase III trials utilizing this drug combination are currently ongoing in the adjuvant and metastatic settings. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis Aventis; Roche
Interrelations of Lead Levels in Bone, Venous Blood, and Umbilical Cord Blood with Exogenous Lead Exposure through Maternal Plasma Lead in Peripartum Women
Authors: Hung-Yi Chuang, Joel Schwartz, Teresa Gonzales-Cossio, Marlene Cortez Lugo, Eduardo Palazuelos, Antonio Aro, Howard Hu, Mauricio Hernandez-Avila
Journal: Environmental Health Perspectives (2001)

Recent research has raised the possibility that fetal lead exposure is not estimated adequately by measuring lead content in maternal whole blood lead because of the variable partitioning of lead in whole blood between plasma and red blood cells. Lead in maternal plasma may derive in large part from maternal bone lead stores. In this study we aimed to estimate the contribution of maternal whole blood lead, maternal bone lead levels, and environmental lead to umbilical cord blood lead levels (as a measure of fetal lead exposure). In the model, we assumed that lead from all of these sources reaches the fetus through the maternal plasma lead pathway. In 1994-1995, we recruited 615 pregnant women for a study of lead exposure and reproductive outcomes in Mexico City. We gathered maternal and umbilical cord blood samples within 12 hr of each infant's delivery and measured maternal lead levels in cortical bone and trabecular bone by a K-X-ray fluorescence (K-XRF) instrument within 1 month after delivery. We administered a questionnaire to assess use of lead-glazed ceramics (LGC) to cook food and we obtained data on regional air lead levels during the 2 months before delivery. We used structural equation models (SEMs) to estimate plasma lead as the unmeasured (latent) variable and to quantify the interrelations of plasma lead, the other lead biomarkers, and environmental lead exposure. In the SEM analysis, a model that allowed plasma lead to vary freely from whole blood lead explained the variance of cord blood lead (as reflected by a total model R(2); R(2) = 0.79) better than did a model without plasma lead (r(2) = 0.67). Cortical bone lead, trabecular bone lead, use of LGC, and mean air lead level contributed significantly to plasma lead. The exchange of lead between plasma and red blood cells was mostly in the direction of plasma to cells. According to the final model, an increase in trabecular bone lead and cortical bone lead was associated with increases in cord blood lead of 0.65 and 0.25 microg/dL, respectively. An increase of 0.1 microg/m(3) in air lead was associated with an increase in the mean level of fetal cord blood lead by 0.67 microg/dL. With one additional day of LCG use per week in the peripartum period, the mean fetal blood lead level increased by 0.27 microg/dL. Our analyses suggested that maternal plasma lead varies independently from maternal whole blood lead and that the greatest influences on maternal plasma lead are maternal bone lead stores, air lead exposures, and recent cooking with LGC. The contributions from endogenous (bone) and exogenous (environmental) sources were relatively equal. Measurement of plasma and bone lead may be important in accurately assessing fetal lead exposure and its major sources, particularly if exogenous exposures decline.
Abstract B36: The role of the microRNA-200 family in the regulation of tumor cell signaling and metastasis in lung cancer
Authors: Jonathon D. Roybal, David H. Peng, Christin Ungewiss, Pijus K. Mandal, John S. McMurray, Lauren A. Byers, Don L. Gibbons
Journal: Cancer Research (2015)

Abstract Lung cancer is the deadliest cancer in the United States due primarily to the development of metastatic disease, resulting in a 16% five year overall survival. Regrettably response rates are poor with the current modalities used to treat patients, which implies that a greater understanding of the biology of invasion and metastasis is indispensable. It is thought that the epithelial-mesenchymal transition (EMT) plays a crucial role in regulating invasion, migration, and metastasis. The microRNA-200 family (miR-200) is a key maintenance factor of the epithelial phenotype by regulating EMT and metastatic potential, although the mechanistic details of this regulation are incompletely understood. Recent research has demonstrated that miRNAs are capable of regulating the target mRNAs that coordinate intracellular signaling pathways. Using our mutant Kras and p53 murine model of metastatic lung adenocarcinoma, we have shown through Reverse Phase Protein Array (RPPA) profiling that high levels of miR-200 in poorly metastatic lung tumor cells can suppress cancer-promoting signaling molecules, such as Signal Transducer and Activator of Transcription 3 (STAT3). In contrast, highly metastatic lung tumor cells with low miR-200 expression have STAT3 activation and increased migratory and invasive properties. Utilizing pharmacologic approaches to inhibit STAT3 in highly metastatic lung tumor cells decreased their ability to migrate and invade. Our data suggests that the STAT3 pathway is under the control of miR-200 and inhibition in metastatic lung cancer could provide benefit to lung cancer patients as a potential treatment option. Citation Format: Jonathon D. Roybal, David H. Peng, Christin Ungewiss, Pijus K. Mandal, John S. McMurray, Lauren A. Byers, Don L. Gibbons. The role of the microRNA-200 family in the regulation of tumor cell signaling and metastasis in lung cancer. [abstract]. In: Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr B36. doi:10.1158/1538-7445.CHTME14-B36
Marriages
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Largest-ever antismoking effort aims to form grass-roots coalitions
Authors: P. Cotton
Journal: JAMA (1992)

THE FEDERAL government is beginning to disburse what will be a total of $135 million for a 7-year program designed to establish grass-roots antismoking coalitions. The American Cancer Society is pitching in with another $25 million to $30 million. The American Stop Smoking Intervention Study (ASSIST) is not a study at all, but an attempt to put into action findings from the National Cancer Institute's research studies that have proven the efficacy of methods to help people quit or not start smoking. Contracts have been awarded to 17 state health departments for a total of more than $7 million this year alone. "This is, quite simply, the largestever national program to combat public health enemy number one—cigarette smoking," said Louis W. Sullivan, MD, secretary of the Department of Health and Human Services, when announcing the contract recipients at a press conference in Washington, DC. He predicts that the program will